Research Forensic Library
A program of the Global Forensic and Justice Center at Florida International University
Center for Forensic Science Research & Education
| Title | Authors | Source | Link | Year |
|---|---|---|---|---|
| Evaluation of Xylazine Test Strips (BTNX) for Drug Checking Purposes | Krotulski, AJ; Shinefeld, J; DeBord, J; Teixeira da Silva, D; Logan, BK. | CFSRE; 2023 | www.cfsre.org/nps-discovery/drug-checking/evaluation-of-xylazine-test-strips-btnx-for-drug-checking-purposes | 2023 |
| Recommended Scope for NPS Testing in the United States: Q1 2023 | Alex Krotulski, Donna Papsun, Dani Mata, Kayla Ellefson, Elisa Shoff, Szabolcs Sofalvi, Svanto Vikingsson, Michael Truver, Celia Modoll, and Barry Logan | SOFT, CFSRE; February 2023 | www.cfsre.org/nps-discovery/scope-recommendations | 2023 |
| N-Desethyl Isotonitazene | Alex J. Krotulski, PhD; Reta Newman, MA; Michael Gilbert, BS; Sara E. Walton, MS; Melissa F. Fogarty, MSFS, D-ABFT-FT; and Barry K. Logan, PhD, F-ABFT | CFSRE; December 20, 2022 | www.cfsre.org/nps-discovery/monographs | 2022 |
| Drug Checking Quarterly Report – Q3 2022 | Alex J. Krotulski, PhD; Jen Shinefeld, MS; Joshua DeBord, PhD; Daniel Teixeira da Silva, MD; and Barry K. Logan, PhD, F-ABFT | CFSRE, PDPH; November 2022 | www.cfsre.org/nps-discovery/drug-checking/drug-checking-q3-2022-philadelphia-pennsylvania-usa | 2022 |
| ToxIC Fentalog Study Group – Quarterly NPS Report – Q3 | Alex Manini, MD; Alex J Krotulski, PhD; Sara E. Walton, MS; Paul Wax, MD; Jeffery Brent, MD, PhD; Kim Aldy, DO; Alexandra Amaducci, DO; Dlane Calello, MD; Adrienne Hughes, MD; Anthony Pizon, MD; Michael Levine, MD; Evan Schwarz, MD; Bryan Judge, MD; and Barry K. Logan, PhD, F-ABFT | CSFRE; TIC; ACMT; October 2022 | www.cfsre.org/nps-discovery/clinical-reports | 2022 |
| NPS Discovery Toolkit: N-Pyrrolidino Etonitazene | Sara E. Walton, MS; Alex J. Krotulski, PhD; Melissa F. Fogarty, MSFS, D-ABFT-FT; Donna M. Papsun, MS, D-ABFT; and Barry K. Logan, PhD, F-ABFT | CFSRE; October 2022 | www.cfsre.org/nps-discovery/analytical-toolkits | 2022 |
| NPS Benzodiazepines in the United States – Q3 Trend Report | Alex J. Krotulski, PhD; Sara E. Walton, MS; Amanda L.A. Mohr, MSFS, D-ABFT-FT; and Barry K. Logan, PhD, F-ABFT | CFSRE; October 2022 | www.cfsre.org/nps-discovery/trend-reports/nps-benzodiazepines/report/49?trend_type_id=1 | 2022 |
| Fentanyl Purity, Potency, & Synthesis: Real-Time Testing of Opioid Drug Products in the United States | Krotulski, AJ, Shinefeld, J, DeBord, J, Logan, BK | CFSRE; August, 2022 | www.npsdiscovery.org/fentanyl-purity-potency-synthesis-real-time-testing-of-opioid-drug-products-in-the-united-states/ | 2022 |
| Recommended Scope for NPS Testing in the United States: Q2 2022 | Alex Krotulski, Donna Papsun, Dani Mata, Kayla Ellefsen, Elisa Shoff, Kevin Shanks, Szabolcs Sofalvi, Wayne Lewallen, Svante Vikingsson, and Barry Logan | CFSRE; July 2022 | www.npsdiscovery.org/reports/nps-scope-recommendations/ | 2022 |
| N-Propyl Butylone | Alex J. Krotulski, PhD; Vanquilla Shellman Francis, PhD; Melissa F. Fogarty, MSFS, D-ABFTFT; Sara E. Walton, MS; and Barry K. Logan, PhD, F-ABFT | CFSRE; July 21, 2022 | www.npsdiscovery.org/reports/monographs/ | 2022 |
| NPS Benzodiazepines, NPS Opioids, NPS Stimulants & Hallucinogens, and Synthetic Cannabinoids – Q2 2022 Trend Reports | Alex J. Krotulski, PhD; Sara E. Walton, MS; Amanda L.A. Mohr, MSFS, D-ABFT-FT; and Barry K. Logan, PhD, F-ABFT | CFSRE; July 13, 2022 | www.npsdiscovery.org/reports/trend-reports/ | 2022 |
| CH-FUBIATA | Alex J. Krotulski, PhD; Jennifer Shinefeld, MS; Melissa F. Fogarty, MSFS, D-ABFT-FT; Joshua DeBord, PhD; and Barry K. Logan, PhD, F-ABFT | CFSRE; June 21, 2022 | www.npsdiscovery.org/reports/monographs/ | 2022 |
| Bromazolam Prevalence Surging Across the United States Driven In Part by Increasing Detections Alongside Fentanyl | Donna M. Papsun, MS, D-ABFT-FT; Alex J. Krotulski, PhD; Rebecca Mastrovito, MS; Sara E. Walton, MS; and Barry K. Logan, PhD, F-ABFT | CFSRE; June 15, CFSRE; June 15, 2022 | www.npsdiscovery.org/bromazolam-prevalence-surging-across-the-united-states-driven-in-part-by-increasing-detections-alongside-fentanyl/ | 2022 |
| N-Cyclohexyl Butylone | Alex J. Krotulski, PhD; Vanquilla Shellman Francis, PhD; Ryan Farrell; Zackery Roberson, PhD; Melissa F. Fogarty, MSFS, D-ABFT-FT; Sara E. Walton, MS; and Barry K. Logan, PhD, F-ABFT | CFSRE; June 9, 2022 | www.npsdiscovery.org/reports/monographs/ | 2022 |
| Drug Checking (Q2 2022): Philadelphia, Pennsylvania, USA | Alex J. Krotulski, PhD; Jen Shinefeld, MS; Jeffrey Hom, MD, MPH; Sara E. Walton, BS; Joshua DeBord, PhD; Barry K. Logan, PhD, F-ABFT | CFSRE; June 7, 2022 | www.npsdiscovery.org/drug-checking-q2-2022-philadelphia-pennsylvania-usa/ | 2021 |
| ADB-5’Br-BINACA | Alex J. Krotulski, PhD; Jennifer Shinefeld, MS; Robert M. Schelkun, MS; Donna M. Iula, PhD; Melissa F. Fogarty, MSFS, D-ABFT-FT; Joshua DeBord, PhD; and Barry K. Logan, PhD, F-ABFT | CFSRE; May 26, 2022 | www.npsdiscovery.org/wp-content/uploads/2022/05/ADB-5Br-BINACA_055622_CFSRE-Chemistry_Report.pdf | 2022 |
| BZO-4en-POXIZID | Alex J. Krotulski, PhD; Ryan Farrell; Armando Vargas; Melissa F. Fogarty, MSFS, DABFT-FT; Sara E. Walton, MS; and Barry K. Logan, PhD, F-ABF | CFSRE; May 19, 2022 | www.npsdiscovery.org/reports/monographs/ | 2022 |
| Recommended Scope for NPS Testing in the United States – Q1 2022 | Alex Krotulski, Donna Papsun, Dani Mata, Kayla Ellefsen, Elisa Shoff, Kevin Shanks, Szabolcs Sofalvi, Wayne Lewallen, Svante Vikingsson, and Barry Logan | CFSRE; May 12, 2022 | www.npsdiscovery.org/reports/nps-scope-recommendations/ | 2022 |
| N-Cyclohexyl Methylone | Alex J. Krotulski, PhD; Vanquilla Shellman Francis, PhD; Ryan Farrell; Kaitlin Schilde, MSFS; Melissa F. Fogarty, MSFS, D-ABFT-FT; Sara E. Walton, MS; and Barry K. Logan, PhD, F-ABFT | CFSRE; May 9, 2022 | www.npsdiscovery.org/wp-content/uploads/2022/05/N-Cyclohexyl-Methylone_050922_CFSRE-Chemistry_Report.pdf | 2022 |
| ADB-5Br-INACA | Alex J. Krotulski, PhD; Ryan Farrell; Zackery Roberson, PhD; Melissa F. Fogarty, MSFS, D-ABFT-FT; Sara E. Walton, MS; and Barry K. Logan, PhD, F-ABFT | CFSRE; May 17, 2022 | www.npsdiscovery.org/wp-content/uploads/2022/05/ADB-5Br-INACA_051721_CFSRE-Chemistry_Report.pdf | 2022 |
| MDMB-5Br-INACA | Alex J. Krotulski, PhD; Ryan Farrell; Kaitlin Schilde, MSFS; Melissa F. Fogarty, MSFS, D-ABFT-FT; Sara E. Walton, MS; and Barry K. Logan, PhD, F-ABFT | CFSRE; May 17, 2022 | www.npsdiscovery.org/wp-content/uploads/2022/05/MDMB-5Br-INACA_051721_CFSRE-Chemistry_Report.pdf | 2022 |
| CH-PIATA | Alex J. Krotulski, PhD; Ryan Farrell; Amanda Mohaupt, MSFS; Melissa F. Fogarty, MSFS, D-ABFT-FT; Sara E. Walton, MS; and Barry K. Logan, PhD, F-ABFT | CFSRE; April 29, 2022 | www.npsdiscovery.org/wp-content/uploads/2022/04/CH-PIATA_042922_CFSRE-Chemistry_Report.pdf | 2021 |
| Synthetic Stimulant Market Rapidly Changing as N,N-Dimethylpentylone Replaces Eutylone in Drug Supply Typically Sold as “Ecstasy” or “Molly” | Alex J. Krotulski, PhD; Melissa F. Fogarty, MS, D-ABFT-FT; Donna M. Papsun, MS, D-ABFT-FT; Michael Lamb, MS, D-ABFT-FT; Sara E. Walton, MS; and Barry K. Logan, PhD, F-ABFT | CFSRE; April 2022 | www.npsdiscovery.org/reports/public-health-alerts/ | 2022 |
| Synthetic Cannabinoids in the United States: Trend Report: Q1, 2022 | Alex J. Krotulski, PhD; Sara E. Walton, MS; Amanda L.A. Mohr, MSFS, D-ABFT-FT; and Barry K. Logan, PhD, F-ABFT | CFSRE; April 2022 | www.npsdiscovery.org/reports/trend-reports/ | 2022 |
| Drug Checking Report – Q1 2022: Philadelphia, Pennsylvania, USA | Alex J. Krotulski, PhD; Jen Shinefeld, MS; Jeffrey Hom, MD, MPH; Sara E. Walton, MS; and Barry K. Logan, PhD, F-ABFT | CSFRE; March 22, 2022 | www.npsdiscovery.org/reports/drug-checking/ | 2022 |
| N,N-Dimethylpentylone | Alex J. Krotulski, PhD; Sara E. Walton, MS; Melissa F. Fogarty, MSFS, DABFT- FT; Donna M. Papsun, MS, D-ABFT; Barry K. Logan, PhD, F-ABFT | Center for Forensic Science Research and Education; December 17, 2021 | www.npsdiscovery.org/wp-content/uploads/2021/12/NN-Dimethylpentylone_121721_CFSRE-Toxicology_Report.pdf | 2021 |
| Adverse Effects Linked to Next Generation Opioids Reported in Patients Presenting to Emergency Departments After Suspected Opioid Overdose | Alex Manini, MD; Alex J. Krotulski, PhD; Sara E. Walton, MS; Paul Wax, MD; Jeffery Brent, MD, PhD; Kim Aldy, DO; Diane Calello, MD; Alexandra Amaducci, DO; Evan Schwarz, MD; Bryan Judge, MD; Michael Levine, MD; Barry K. Logan, PhD, F-ABFT | Center for Forensic Science Research and Education; December 3, 2021 | www.npsdiscovery.org/adverse-effects-linked-to-next-generation-opioids-reported-in-patients-presenting-to-emergency-departments-after-suspected-opioid-overdose/ | 2021 |
| N-Piperidinyl Etonitazene | Alex J. Krotulski, PhD; Alex Manini, MD; Diane Calello, MD; Jeff Brent, MD, PhD; Paul Wax, MD; Kim Aldy, MD; Sara E. Walton, MS; Melissa F. Fogarty, MSFS, D-ABFT-FT; and Barry K. Logan, PhD, F-ABFT | Center for Forensic Science Research and Education; November 22, 2021 | www.npsdiscovery.org/wp-content/uploads/2021/11/N-Piperidinyl-Etonitazene_112221_ToxicologyAnalyticalReport.pdf | 2021 |
| ADB-PHETINACA | Alex J. Krotulski, PhD; Alex Manini, MD; Diane Calello, MD; Jeff Brent, MD, PhD; Paul Wax, MD; Kim Aldy, MD; Sara E. Walton, MS; Melissa F. Fogarty, MSFS, D-ABFT-FT; and Barry K. Logan, PhD, F-ABFT | Center for Forensic Science Research and Education; November 19, 2021 | www.npsdiscovery.org/wp-content/uploads/2021/11/ADB-PHETINACA_111921_ToxicologyAnalyticalReport.pdf | 2021 |
| BZO-CHMOXIZID | Alex J. Krotulski, PhD; Ryan Farrell; Amanda Mohaupt; Melissa F. Fogarty, MSFS, DABFT- FT; and Barry K. Logan, PhD, F-ABFT | NPS Discovery Center for Forensic Science Research and Education; November 18, 2021 | www.npsdiscovery.org/wp-content/uploads/2021/11/BZO-CHMOXIZID_111821_CFSRE-Chemistry_Report.pdf | 2021 |
| ADB-FUBIATA | Alex J. Krotulski, PhD; Ryan Farrell; Kaitlin Schilde; Robert M. Schelkun, MS; Donna M. Iula, PhD; Melissa F. Fogarty, MSFS, D-ABFT-FT; and Barry K. Logan, PhD, F-ABFT | Center for Forensic Science Research and Education; November 17, 2021 | www.npsdiscovery.org/wp-content/uploads/2021/11/ADB-FUBIATA_111721_CFSRE-Chemistry_Report.pdf | 2021 |
| BZO-HEXOXIZID | Alex J. Krotulski, PhD; Ryan Farrell; Zackery Roberson; Armando Vargas; Melissa F. Fogarty, MSFS, D-ABFT-FT; and Barry K. Logan, PhD, F-ABFT | Center for Forensic Science Research and Education; October 19, 2021 | www.npsdiscovery.org/wp-content/uploads/2021/10/BZO-HEXOXIZID_101921_CFSRE-Chemistry_Report.pdf | 2021 |
| 5F-BZO-POXIZID | Alex J. Krotulski, PhD; Reta Newman, MA; Michael Gilbert, BS; Melissa F. Fogarty, MSFS, D-ABFT-FT; and Barry K. Logan, PhD, F-ABF | Center for Forensic Science Research and Education; October 19, 2021 | www.npsdiscovery.org/wp-content/uploads/2021/10/5F-BZO-POXIZID_101921_CFSRE-Chemistry_Report.pdf | 2021 |
| Synthetic Cannabinoids in the United States | Alex J. Krotulski, PhD; Sara E. Walton, MS; Amanda L.A. Mohr, MSFS, D-ABFT-FT; Barry K. Logan, PhD, F-ABFT | Center for Forensic Science Research and Education; October 13, 2021 | www.npsdiscovery.org/wp-content/uploads/2021/10/2021-Q3_Synthetic-Cannabinoids_Trend-Report.pdf | 2021 |
| Fluclotizolam | Alex J. Krotulski, PhD; Sara E. Walton, MS; Donna M. Papsun, MS, D-ABFT-FT; Melissa F. Fogarty, MSFS, D-ABFT-FT; Barry K. Logan, PhD, F-ABFT | CSFRE; November 5 | www.npsdiscovery.org/reports/monographs/ | 2021 |
| Recommended Scope for NPS Testing in the United States: Q3 2021 | A Krotulski, D Papsun, D Mata, K Ellefsen, E Shoff, K Shanks, S Sofalvi, S Kacinko, W Lewallen, S Vikingsson, B Logan | CFSRE; Quarter 3, November | www.npsdiscovery.org/reports/nps-scope-recommendations/ | 2021 |
| Drug Supply Assessment: Q3 2021 – Philadelphia, Pennsylvania | Alex J. Krotulski, PhD; Jen Shinefeld, MS; et al | Center for Forensic Science Research and Education; October 2021 | www.npsdiscovery.org/drug-supply-assessment-q3-2021-philadelphia-pennsylvania-usa/ | 2021 |
| Metodesnitazene | Alex J. Krotulski, PhD; Matthew Juhascik, PhD, F-ABFT et al | The Center for Forensic Science Research and Education; September 2021 | t.co/YUsxge5hEy?amp=1 | 2021 |
| New Systematic Naming for Synthetic Cannabinoid “MDA-19” and Its Related Analogues: BZO-HEXOXIZID, 5F-BZO-POXIZID, and BZO-POXIZID | RM Schelkun, MS; AJ Krotulski, PhD; DM Iula, PhD; BK Logan, PhD, F-ABFT | CFSRE; Cayman Chemical; NPS Discovery; August 31, 2021 | www.npsdiscovery.org/wp-content/uploads/2021/08/New-Systematic-Naming-for-MDA-19-and-Related-Analogues_NPS-Discovery_083121.pdf | 2021 |
Global Forensic and Justice Center
11200 SW 8th Street
Miami, FL 33199
Contact Us